Long-term survival following cladribine (2-chlorodeoxyadenosine) therapy in previously treated patients with chronic lymphocytic leukemia

Annals of Oncology

Volumn 7, Issue 4, 1996, Pages 373-379

  Juliusson, G ^a,b   Liliemark, J ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

Author keywords

2 CdA; Autologous blood stem cell; CLL; Complete remission; Fludarabine; Nucleoside analogue; Transplantation; Treatment

Indexed keywords

CLADRIBINE;

ADULT; AGED; ARTICLE; B CELL LEUKEMIA; BLOOD TOXICITY; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; DRUG EFFICACY; FEMALE; HERPES ZOSTER; HUMAN; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; PNEUMONIA; PRIORITY JOURNAL; SEPTICEMIA; SURVIVAL TIME; TREATMENT OUTCOME;

EID: 0030018146     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.annonc.a010604     Document Type: Article

References (37)

1. Montserrat E, Rozman C. Chronic lymphocytic leukemia: Present status. Ann Oncol 1995; 6: 219-35.
2. Pott-Hoeck C, Hiddeman W. Purine analogs in the treatment of low-grade lymphomas and chronic lymphocytic leukemias. Ann Oncol 1995; 6: 421-33.
3. Montgomery JA, Hewson K. Synthesis of potential anti-cancer agents. XX. 2-fluoropurines. J Am Chem Soc 1960; 82: 463-8.
4. Keating MJ. Fludarabine phosphate in the treatment of chronic lymphocytic leukemia. Semin Oncol 1990; 17 (Suppl 8): 49-62.
5. Johnson SA, Hiddemann W, Coiffier B et al. A randomised comparison between fludarabine and cyclophosphamide, adriamycin and prednisolone in the treatment of chronic lymphocytic leukaemia. Br J Haematol 1994; 87 (Suppl 1): 169 (Abstr 661).
6. Rai KR, Peterson B, Kolitz J et al. for CALGB, SWOG, CTG/ NCI-C, ECOG and NCI. Fludarabine induces a high complete remission rate in previously untreated patients with active chronic lymphocytic leukemia. A randomized inter-group study. Blood 1995; 86 (Suppl 1): 607a (Abstr 2414).
7. Keating M, Lerner S, O'Brien S et al. Long-term follow-up of patients with chronic lymphocytic leukemia receiving fludarabine regimens as initial therapy. Proc Am Soc Clin Oncol 1995; 14: 337 (Abstr 1012).
8. Beutler E. Cladribine (2-chlorodeoxyadenosine). Lancet 1992; 340: 952-6.
9. Piro LD, Carrera CJ, Carson DA, Beutler E. Lasting remission in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. N Engl J Med 1990; 322: 1117-21.
10. Kay AC, Saven A, Carrera CJ et al. 2-Chlorodeoxyadenosine treatment of low-grade lymphomas. J Clin Oncol 1992; 10: 371-7.
11. O'Brien S, Kurzrock R, Duvic M et al. 2-Chlorodeoxyadenosine therapy in patients with T-cell lymphoproliferative disorders. Blood 1994; 84: 733-8.
12. Dimopoulos MA, Kantarjian H, Weber D et al. Primary therapy of Waldenström's macroglobulinemia with 2-chlorodeoxyadenosine. J Clin Oncol 1994; 12: 2694-8.
13. Santana VM, Hurwitz CA, Blakley RL et al. Complete hematologic remissions induced by 2-chlorodeoxyadenosine in children with newly diagnosed acute myeloid leukemia. Blood 1994; 84: 1237-42.
14. Juliusson G, Liliemark J. 2-Chlorodeoxyadenosine (CdA) with and without cytosin arabinoside (ara-C) and idarubicin for acute myeloid and lymphoid leukemia - clinical and pharmacokinetic studies. Br J Haematol 1994; 87 (Suppl 1): 12 (Abstr 48).
15. Saven A, Foon KA, Piro LD. 2-Chlorodeoxyadenosine-induced complete remission in Langerhans-cell histiocytosis. Ann Intern Med 1994; 121: 430-2.
16. Sipe JC, Romine JS, Koziol JA et al. Cladribine in treatment of chronic progressive multiple sclerosis. Lancet 1994; 344: 9-13.
17. Saven A, Carrera CJ, Carson DA et al. 2-Chlorodeoxyadenosine treatment of refractory chronic lymphocytic leukemia. Leuk Lymphoma 1991; 5 (Suppl 1): 133-8.
18. Saven A, Lemon RH, Kosty M et al. 2-Chlorodeoxyadenosine activity in patients with untreated chronic lymphocytic leukemia. J Clin Oncol 1995; 13: 570-4.
19. Delannoy A, Martial P, Gala JL et al. 2-Chlorodeoxyadenosine (CdA) for patients with previously untreated chronic lymphocytic leukemia (CLL). Leukemia 1995; 9: 1130-5.
20. Mulligan SP, Eliadis P, Dale B et al. for the Australian Leukemia Study Group. 2-Chlorodeoxyadenosine in previously untreated chronic lymphocytic leukemia - preliminary analysis from the Australian Leukemia Study Group trial. Blood 1995; 86 (Suppl 1): 349a (Abstr 1385)
21. Juliusson G, Johnson SAN, Christiansen I et al. Oral 2-chlorodeoxyadenosine as primary treatment for symptomatic chronic lymphocytic leukemia. Blood 1993; 82 (Suppl): 141a (Abstr 551)
22. Juliusson G, Christiansen I, Hansen MM et al. Oral Cladribine as primary therapy for patients with B-cell chronic lymphocytic leukemia. J Clin Oncol 1996; 14: in press.
23. Juliusson G, Liliemark J. High complete remission rate from 2-chloro-2′-deoxyadenosine (CdA) in previously treated patients with B-cell chronic lymphocytic leukemia: Response predicted by rapid decrease of blood lymphocyte count. J Clin Oncol 1993; 11: 679-89.
24. Cheson BD, Bennett JM, Rai KR et al. Guidelines for clinical protocols for chronic lymphocytic leukemia: Recommendations of the National Cancer Institute-sponsored Working Group. Am J Hematol 1988; 29: 152-63.
25. Binet JL, Auquier A, Dighiero G et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981; 48: 198-206.
26. Juliusson G, Elmhorn-Rosenborg A, Liliemark J. Response to 2-chlorodeoxyadenosine in patients with B-cell chronic lymphocytic leukemia resistant to fludarabine. N Engl J Med 1992; 327: 1056-61.
27. Juliusson G, Liliemark J. Retreatment of B-cell chronic lymphocytic leukemia with 2-chlorodeoxyadenosine (CdA) at relapse following CdA-induced remission. No acquired resistance. Leuk Lymph 1994; 13: 75-80.
28. The French Cooperative Group on CLL, Johnson S, Smith AG et al. Fludarabine versus cyclophosphamide, doxorubicin, prednisone (CAP) for the treatment of advanced stage chronic lymphocytic leukemia. Results of a multicenter prospective randomized study. Lancet 1996; in press.
29. Rabinowe SN, Soiffer RJ, Gribben JG et al. Autologous and allogeneic bone marrow transplantation for poor prognosis patients with B-cell chronic lymphocytic leukemia. Blood 1993; 82: 1366-76.
30. Khouri IF, Keating MJ, Vriesendorp HM et al. Autologous and allogeneic bone marrow transplantation for chronic lymphocytic leukemia: Preliminary results. J Clin Oncol 1994; 12: 748-58.
31. Betticher DC, Fey MF, von Rohr A et al. High incidence of infections after 2-chlorodeoxyadenosine (2-CDA) therapy in patients with malignant lymphomas and chronic and acute leukaemias. Ann Oncol 1994; 5: 57-64.
32. O'Brien S, Kantarjian H, Estey E et al. Lack of effect of 2-chlorodeoxyadenosine therapy in patients with chronic lymphocytic leukemia refractory to fludarabine therapy. N Engl J Med 1994; 330: 319-22.
33. Juliusson G. Immunologic and genetic abnormalities in chronic lymphocytic leukaemia. Drugs 1994; 47 (Suppl 6): 19-29.
34. Juliusson G, Lenkei R, Liliemark J. Flow cytometry of blood and bone marrow cells in hairy cell leukemia. Phenotype of hairy cells and lymphocyte subsets following treatment with 2-chlorodeoxyadenosine. Blood 1994; 83: 3672-81.
35. Liliemark J, Albertioni F, Hassan M, Juliusson G. On the bioavailability of oral and subcutaneous 2-chloro-2′-deoxyadenosine in humans: Alternative routes of administration. J Clin Oncol 1992; 10: 1514-8.
36. Liliemark J, Juliusson G. Cellular pharmacokinetics of 2-chloro-2′-deoxyadenosine nucleotides: Comparison of intermittent and continuous intravenous infusion and subcutaneous and oral administration in leukemia patients. Clin Cancer Res 1995; 1: 385-90.
37. Juliusson G, Heldal D, Hippe E et al. Subcutaneous injection of 2-chlorodeoxyadenosine for symptomatic hairy cell leukemia. J Clin Oncol 1995; 13: 989-95.